{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:10:34Z","timestamp":1790745034821,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03569-1","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:56:14Z","timestamp":1741870574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs"],"prefix":"10.1186","volume":"25","author":[{"given":"Linwu","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-5078","authenticated-orcid":false,"given":"Yangkai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"22","key":"3569_CR1","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1097\/CM9.0000000000001819","volume":"134","author":"CL Guo","year":"2021","unstructured":"Guo CL, Mei JD, Jia YL, Gan FY, Tang YD, Liu CW, et al. Impact of thymosin \u03911 as an Immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis. Chin Med J. 2021;134(22):2700\u20139.","journal-title":"Chin Med J"},{"issue":"12","key":"3569_CR2","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.21037\/jtd.2019.11.30","volume":"11","author":"C Zhang","year":"2019","unstructured":"Zhang C, Wang L, Li W, Huang Z, Liu W, Bao P, et al. Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience. J Thorac Disease. 2019;11(12):5463\u201373.","journal-title":"J Thorac Disease"},{"issue":"3","key":"3569_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/tlcr.2019.06.08","volume":"8","author":"A Yoshimura","year":"2019","unstructured":"Yoshimura A, Uchino J, Hasegawa K, Tsuji T, Shiotsu S, Yuba T, et al. Carcinoembryonic antigen and CYFRA 21\u2013\u20091 responses as prognostic factors in advanced non-small cell lung cancer. Translational Lung cancer Res. 2019;8(3):227\u201334.","journal-title":"Translational Lung cancer Res"},{"issue":"6","key":"3569_CR4","doi-asserted-by":"publisher","first-page":"188967","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 Years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochim Et Biophys Acta Reviews cancer. 2023;1878(6):188967.","journal-title":"Biochim Et Biophys Acta Reviews cancer"},{"issue":"Suppl 1","key":"3569_CR5","first-page":"S23","volume":"8","author":"N Karachaliou","year":"2019","unstructured":"Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Translational cancer Res. 2019;8(Suppl 1):S23\u201347.","journal-title":"Translational cancer Res"},{"issue":"10","key":"3569_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, et al. Befotertinib (D-0316) versus Icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respiratory Med. 2023;11(10):905\u201315.","journal-title":"Lancet Respiratory Med"},{"issue":"10","key":"3569_CR7","first-page":"5771","volume":"37","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi A, Oguri T, Sone K, Ito K, Kitamura Y, Inoue Y, et al. Predictive and prognostic value of CYFRA 21\u2013\u20091 for advanced Non-small cell lung Cancer treated with EGFR-TKIs. Anticancer Res. 2017;37(10):5771\u20136.","journal-title":"Anticancer Res"},{"issue":"6","key":"3569_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cllc.2017.04.015","volume":"18","author":"T Jiang","year":"2017","unstructured":"Jiang T, Cheng R, Zhang G, Su C, Zhao C, Li X, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: A multicenter study. Clin Lung Cancer. 2017;18(6):631\u2013e92.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"3569_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000357129","volume":"86","author":"J Fukihara","year":"2014","unstructured":"Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, et al. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. Oncology. 2014;86(2):86\u201393.","journal-title":"Oncology"},{"key":"3569_CR10","doi-asserted-by":"publisher","first-page":"680804","DOI":"10.3389\/fonc.2021.680804","volume":"11","author":"R Jin","year":"2021","unstructured":"Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, et al. EGFR-Mutated squamous cell lung Cancer and its association with outcomes. Front Oncol. 2021;11:680804.","journal-title":"Front Oncol"},{"issue":"6","key":"3569_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/15384047.2018.1435222","volume":"19","author":"Y Liu","year":"2018","unstructured":"Liu Y. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review. Cancer Biol Ther. 2018;19(6):445\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"3569_CR12","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.32596","volume":"146","author":"M Bergqvist","year":"2020","unstructured":"Bergqvist M, Christensen HN, Wiklund F, Bergstr\u00f6m S. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010\u20132016 in Sweden: A nationwide observational study. Int J Cancer. 2020;146(9):2510\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"3569_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/CBM-170885","volume":"22","author":"AR Baek","year":"2018","unstructured":"Baek AR, Seo HJ, Lee JH, Park SW, Jang AS, Paik SH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer. Cancer Biomark A. 2018;22(1):55\u201362.","journal-title":"Cancer Biomark A"},{"issue":"11","key":"3569_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/sj.bjc.6601851","volume":"90","author":"JL Pujol","year":"2004","unstructured":"Pujol JL, Molinier O, Ebert W, Daur\u00e8s JP, Barlesi F, Buccheri G, et al. CYFRA 21\u2013\u20091 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90(11):2097\u2013105.","journal-title":"Br J Cancer"},{"issue":"5","key":"3569_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-023-00991-5","volume":"18","author":"K Morimoto","year":"2023","unstructured":"Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N, et al. Clinical efficacy and safety of First- or Second-Generation EGFR-TKIs after osimertinib resistance for EGFR mutated lung cancer: A prospective exploratory study. Target Oncol. 2023;18(5):657\u201365.","journal-title":"Target Oncol"},{"key":"3569_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/CMAR.S349082","volume":"14","author":"X Mao","year":"2022","unstructured":"Mao X, Liu J, Hu F, Niu Y, Pan F, Fu X, et al. Serum NSE is early marker of transformed neuroendocrine tumor after EGFR-TKI treatment of lung adenocarcinoma. Cancer Manage Res. 2022;14:1293\u2013302.","journal-title":"Cancer Manage Res"},{"issue":"4","key":"3569_CR17","doi-asserted-by":"publisher","first-page":"e32697","DOI":"10.1097\/MD.0000000000032697","volume":"102","author":"X Chen","year":"2023","unstructured":"Chen X, Li D, Miao K, Shou T, Zhang W. Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. Medicine. 2023;102(4):e32697.","journal-title":"Medicine"},{"issue":"32","key":"3569_CR18","doi-asserted-by":"publisher","first-page":"e26911","DOI":"10.1097\/MD.0000000000026911","volume":"100","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Shou L, Guo Q, Bao Y, Xu X, An S, et al. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report. Medicine. 2021;100(32):e26911.","journal-title":"Medicine"},{"issue":"4","key":"3569_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cllc.2015.11.012","volume":"17","author":"KJ Suh","year":"2016","unstructured":"Suh KJ, Keam B, Kim M, Park YS, Kim TM, Jeon YK, et al. Serum Neuron-Specific enolase levels predict the efficacy of First-Line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with Non-Small cell lung Cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(4):245\u2013e521.","journal-title":"Clin Lung Cancer"},{"key":"3569_CR20","doi-asserted-by":"publisher","first-page":"13607","DOI":"10.2147\/CMAR.S285121","volume":"12","author":"J Dong","year":"2020","unstructured":"Dong J, Tong S, Shi X, Wang C, Xiao X, Ji W, et al. Progastrin-Releasing peptide precursor and Neuron-Specific enolase predict the efficacy of First-Line treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among Non-Small-Cell lung Cancer patients harboring EGFR mutations. Cancer Manage Res. 2020;12:13607\u201316.","journal-title":"Cancer Manage Res"},{"key":"3569_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12967-015-0622-x","volume":"13","author":"E Casta\u00f1\u00f3n","year":"2015","unstructured":"Casta\u00f1\u00f3n E, Rolfo C, Vi\u00f1al D, L\u00f3pez I, Fusco JP, Santisteban M, et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. J Translational Med. 2015;13:257.","journal-title":"J Translational Med"},{"issue":"6","key":"3569_CR22","doi-asserted-by":"publisher","first-page":"e0178676","DOI":"10.1371\/journal.pone.0178676","volume":"12","author":"YP Chang","year":"2017","unstructured":"Chang YP, Chen YM, Lai CH, Lin CY, Fang WF, Huang CH, et al. The impact of de Novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS ONE. 2017;12(6):e0178676.","journal-title":"PLoS ONE"},{"issue":"6","key":"3569_CR23","first-page":"7589","volume":"14","author":"Y Taniguchi","year":"2017","unstructured":"Taniguchi Y, Tamiya A, Nakahama K, Naoki Y, Kanazu M, Omachi N, et al. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncol Lett. 2017;14(6):7589\u201396.","journal-title":"Oncol Lett"},{"issue":"2","key":"3569_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-Mutated lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(2):124\u201336.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"3569_CR25","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, et al. First-line Icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(10):2443\u201350.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"1","key":"3569_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"3569_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"3569_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung Cancer. J Natl Cancer Inst. 2023;115(6):742\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3569_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4143\/crt.2022.1438","volume":"55","author":"W Gu","year":"2023","unstructured":"Gu W, Zhang H, Lu Y, Li M, Yang S, Liang J, et al. EGFR-TKI combined with pemetrexed versus EGFR-TKI monotherapy in advanced EGFR-mutated NSCLC: A prospective, randomized, exploratory study. Cancer Res Treat. 2023;55(3):841\u201350.","journal-title":"Cancer Res Treat"},{"key":"3569_CR30","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor Receptor-Mutated advanced Non-Small-Cell lung Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2023:Jco2302219."}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03569-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03569-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:56:19Z","timestamp":1741870579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03569-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3569"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03569-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(TJ-IRB202408023). Given that this was a retrospective study, the written informed consent was waived and the verbal informed consent has been approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. We informed all participants during the telephone follow-up and obtained their verbal informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}